MIRM vs TGTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MIRM exhibits severe fundamental weakness with a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows impressive revenue growth of 49.8% and strong gross margins, this is offset by a lack of profitability and an extremely stretched valuation (P/B of 15.91). There is a stark divergence between the 'strong_buy' analyst consensus and the bearish reality of aggressive insider selling by the CEO, CFO, and President. The combination of a bearish technical trend (10/100) and deteriorating deterministic scores suggests the current price is speculative and unsupported by fundamentals.
TGTX exhibits a stable financial foundation with a Piotroski F-Score of 6/9 and exceptional profitability margins, yet it faces a significant valuation gap. The stock is trading at $36.96, which is nearly double its Graham Number ($16.79) and Intrinsic Value ($19.39). While revenue growth is explosive at 78%, the company has missed earnings estimates in four consecutive quarters with an average surprise of -41.54%, and YoY earnings growth has turned negative (-6.10%). The disconnect between strong top-line growth and failing bottom-line expectations creates a high-risk profile despite the 'Buy' analyst consensus.
Compare Another Pair
Related Comparisons
MIRM vs TGTX: Head-to-Head Comparison
This page compares Mirum Pharmaceuticals, Inc. (MIRM) and TG Therapeutics, Inc. (TGTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.